Company Overview and News

1
HDFC shares hit record high ahead of Rs 2,800cr AMC IPO next week

12m moneycontrol
Housing Development Finance Corporation share price gained 1.2 percent intraday on Wednesday after its subsidiary HDFC Asset Management Company decided to open the initial public offering for subscription next week.
523405 SLFPF SL IIFL HDFC 532636 HDB 500180 HDFCBANK 500010 HDFC JMFINANCIL SLFPY

0
ASK Group targets $1 billion valuation in share sale

13h livemint
Mumbai: ASK Group is aiming for a valuation of more than $1 billion as it looks to become the first investment and wealth management firm to launch an initial public offering (IPO), said three people aware of the development.
523405 STAN 580001 STAB STAN STAC 2888 SCBFF JMFINANCIL

0
Focus on Bandhan Bank, UltraTech, RCom results

14h thehindubusinessline
Seventeen companies will declare their first quarter results of the current financial year on Wednesday. Among these are Artson Engineering, Bandhan Bank, Foseco India (second quarter and half-year results), GHCL, HT Media, JK Tyres & Industries, JM Financial, Mahindra CIE Automotive, Mastek, MindTree, NIIT Technologies, Pritish Nandy Communications, Responsive Industries, Reliance Communications, Sasken Technologies, UltraTech Cement and Warren Tea.
523405 NIITTECH FOSECOIND RESPONIND 505509 ARTSONEN HTMEDIA 532538 UCLQF 532712 532756 WARRENTEA ULTRACEMCO 500150 532387 532662 532541 RCOM UCLQY PNC 508494 MAHINDCIE 522134 JMFINANCIL

1
HDFC AMC sets IPO price band at Rs 1,095-1,100

15h thehindubusinessline
HDFC Asset Management Company, the country’s second largest mutual fund firm, has fixed a price band of Rs 1,095-1,100 per share for its initial public offering, through which it is estimated to garner Rs 2,800 crore.
523405 SLFPF SL IIFL HDFC 532636 HDB 500180 HDFCBANK 500010 HDFC JMFINANCIL SLFPY

0
Lodha Developers may launch IPO this month to raise ₹ 5,500 crore

2018-07-15 livemint
New Delhi: Lodha Developers plans to launch its initial public offering (IPO) in July to raise ₹ 5,500 crore, people familiar with the real estate firm’s plans have indicated. The Mumbai-based developer had on 6 July received the go-ahead for the share sale. The Lodha Developers IPO, if successful, would be the second biggest initial share sale in the real estate sector after DLF Ltd that raised close to ₹ 9,200 crore in 2007.
523405 JMFINANCIL

0
Tata Consultancy Services, Ltd. (TTNQY) CEO Rajesh Gopinathan on Q1 2019 Results - Earnings Call Transcript

2018-07-11 seekingalpha
Tata Consultancy Services, Ltd. (OTCPK:TTNQY) Q1 2019 Results Earnings Conference Call July 10, 2018 9:30 AM ET
523405 532540 TCS TTNQY JMFINANCIL

0
JM Financial, Axis Bank, IDBI, YES Bank move NCLT to be included as KSS Petron’s creditors

2018-07-11 livemint
Mumbai: Mumbai-based JM Financial Asset Reconstruction and banks including Axis Bank, IDBI Bank and YES Bank have approached the Mumbai bench of the National Company Law Tribunal (NCLT) to be included under the category of financial creditors.
523405 AXBKY YESBANK AXBA 500116 AXB AXISBANK IDBI 532648 YYBKY 532215 JMFINANCIL

0
Building material retailer Shankara plans to raise ₹300 crore through QIP

2018-07-09 livemint
Mumbai: Shankara Building Products Ltd, an organized retailer of home improvement and building material, has appointed an investment bank to raise up to ₹300 crore through a qualified institutional placement (QIP), said two people aware of the development.
523405 OBZIY OBEROIRLTY 533273 IDEA ICLQY HDFC 532822 500010 HDFC JMFINANCIL

0
Four firms file draft share sale documents with regulator to raise up to Rs4,300 crore

2018-07-02 livemint
Mumbai: At least four companies have filed draft share sale documents with the markets regulator, targeting to raise a total of around ₹4,300 crore.
523405 JMFINANCIL

0
Chalet Hotels files for IPO

2018-07-02 thehindubusinessline
K Raheja Corp-promoted Chalet Hotels filed its draft red herring prospectus (DRHP) with market regulator SEBI for its initial public offering.
523405 JMFINANCIL

43
Closing Bell: Global weakness drags Sensex 159 pts, Nifty below 10,700; Infosys, Titan up 2%

2018-07-02 moneycontrol
IPO: Bharat Hotels, which runs five-star properties under 'The LaLiT' brand, has filed draft prospectus with capital markets regulator to garner Rs 1,200 crore through its initial share-sale. The initial public offer (IPO) comprises sale of fresh equity shares to the tune of Rs 1,200 crore, according to the draft papers filed with the Securities and Exchange Board of India (Sebi). Proceeds of the issue will be utilised towards repayment of certain loans availed by the company for other general corporate purposes, reports PTI.
523405 500325 MS.PRE MS.PRF MS.PRG ICLQY MS.PRA 512599 CADILAHC 531795 JUSTDIAL 532321 LNSTY MS GODREJCP 500493 BHARATFORG JMFINANCIL RLNIY SBAZ ANNRY TVSMOTOR GRAPHITE 524804 505192 532822 532424 JSWSTEEL VED BATAINDIA MS.PRI MS.PRK 500180 SMLISUZU AUROPHARMA ADANIENT 500228 RELIANCE 512573 533155 JUBLFOOD GDRJY 532343 535648 RIGD JBLWY HDFCBANK 509488 INDIGO AVANTI IBN ATULAUTO CDLYY 539448 ICICIBANK HDB 532174 ARBQY IDEA 500043 JSTQY

10
HDFC Mutual Fund gets Sebi nod for IPO

2018-06-28 livemint
New Delhi: HDFC Asset Management Co. Ltd, the country’s largest mutual fund, on Thursday received Securities and Exchange Board of India’s (Sebi) approval to float an initial public offer (IPO).
523405 SLFPF SL IIFL HDFC 532636 539516 HDFCNIFETF HDB 500180 HDFCBANK 500010 HDFC JMFINANCIL SLFPY

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...